月度归档： 2026 年 8 月

Vaderis Therapeutics has secured $152 million in Series B financing to fund the global Phase 3 development of its lead candidate engasertib in hereditary hemorrhagic telangiectasia, or HHT. The Swiss company is positioning the program as the first therapy specifically developed for the rare inherited vascular disorder.

Bruker is expanding its life sciences business into human physiology-relevant disease models with a majority investment in MIMETAS, a Leiden-based developer of organ-on-a-chip platforms and advanced human tissue models. Financial terms were not disclosed. MIMETAS will continue to operate under its existing brand and management.

China’s 2026 pomelo export season has begun, with the new crop entering international markets. Alongside stable supply prospects, the industry is placing greater emphasis on consumer-oriented quality standards, moving beyond traditional measures such as fruit size and appearance to attributes including sweetness, peel thickness, and consistency.

世界农化网中文网报道：8月10日，UPL中国旗下子公司燕化永乐在河南许昌召开新品上市会，正式推出三元复配种衣剂"燕化金盾®"（31.8%种菌唑·甲霜灵·噻虫胺）。

2026年6月30日，欧洲食品安全局（EFSA）批准发布第三期新基因组技术（NGT）文献前瞻扫描（horizon scanning）报告，检索截至2026年3月11日，覆盖植物、微生物和动物三大生物类群。这项由欧盟委员会委托的半年期常态化扫描，结论只有一句：本轮所有研究均未提出EFSA既有科学意见未曾考虑过的新危害或新风险。